Japan Cannabis Policy: Laws, Medical Reform & Cannabinoid Regulations

Executive Summary

Japan maintains one of the world's strictest cannabis prohibition regimes, rooted in post-World War II legislation and reinforced by deep cultural stigma. The Cannabis Control Act of 1948, enacted under U.S. occupation, criminalized cultivation, possession, and use of cannabis with penalties including up to seven years imprisonment. Despite global momentum toward medical and recreational legalization, Japan has doubled down on enforcement, with arrests for cannabis violations reaching record highs in recent years. In May 2026, the Japanese government announced plans to ban cannabinol (CBN), a mildly psychoactive cannabinoid, effective June 2026, extending prohibition beyond delta-9-tetrahydrocannabinol (THC) to encompass additional hemp-derived compounds. This move reflects Japan's zero-tolerance approach even as neighboring Asian nations explore medical cannabis frameworks. For international cannabis operators, Japan represents a closed market with no near-term liberalization pathway, while domestic advocates face significant legal and social barriers to reform.

Why This Matters

Japan's cannabis policy shapes the regulatory landscape for the world's third-largest economy and influences broader Asian drug policy. With a population of 125 million and GDP exceeding $4.2 trillion, Japan's prohibition stance affects international trade, pharmaceutical development, and regional diplomatic norms. The country's hardline position creates compliance challenges for multinational companies operating in both Japan and cannabis-legal jurisdictions, particularly in cosmetics, food supplements, and pharmaceutical sectors where cannabidiol (CBD) products face stringent import restrictions. The human cost remains significant. Japanese nationals arrested for cannabis offenses—numbering 6,482 in 2023 according to National Police Agency data—face criminal records that permanently damage employment prospects in a society with limited tolerance for drug-related convictions. Medical patients with conditions potentially treatable by cannabis therapies, including epilepsy, chronic pain, and chemotherapy-induced nausea, have no legal access to cannabinoid medications available in over 40 countries worldwide. Japan's influence extends beyond its borders. As a G7 member and signatory to United Nations drug control treaties, Japan's opposition to cannabis reform provides diplomatic cover for other prohibitionist nations in Asia and globally. The 2026 CBN ban signals that Japan will proactively expand controlled substance lists to counter hemp-derived cannabinoid products, setting a precedent other conservative jurisdictions may follow.

Background and History

Cannabis prohibition in Japan is a relatively recent phenomenon, imposed during the American occupation following World War II. Archaeological evidence indicates cannabis cultivation in Japan dates back at least 10,000 years, with the plant playing central roles in Shinto religious rituals, textile production, and traditional medicine. Hemp fiber was essential for fishing nets, clothing, and ceremonial ropes (shimenawa) that still adorn Shinto shrines today. Cannabis seeds (asanomi) appeared in traditional cuisine, while cannabis-derived preparations featured in the Japanese Pharmacopoeia until the mid-20th century.

Pre-War Cannabis Culture

Prior to 1945, cannabis cultivation was legal, widespread, and culturally integrated throughout Japan. The Meiji government (1868-1912) regulated hemp farming for quality control but imposed no prohibition on cultivation or use. During World War II, the Japanese military encouraged hemp production for rope, canvas, and parachute manufacturing. Farmers grew cannabis as a strategic crop, with cultivation peaking during wartime mobilization. Traditional medicine practitioners used cannabis preparations for pain relief, sedation, and treatment of various ailments. The plant held spiritual significance in Shinto practice, symbolizing purity and used in purification rituals. Cannabis leaves decorated sumo wrestling rings, and hemp cloth wrapped newborns in some regions. This cultural integration meant cannabis carried none of the criminal stigma that would later define Japanese attitudes.

The 1948 Cannabis Control Act

Japan's prohibition regime began with the Cannabis Control Act (Taima Torishimari Hō), enacted July 10, 1948, during the Allied occupation. The law was drafted primarily by U.S. occupation authorities implementing American drug policy frameworks in defeated Japan. General Douglas MacArthur's Supreme Commander for the Allied Powers (SCAP) administration viewed cannabis through the lens of American "reefer madness" propaganda, disregarding Japan's historical relationship with the plant. The 1948 Act established a licensing system for hemp cultivation, restricting legal growing to farmers with prefectural permits for fiber and seed production. Crucially, the law criminalized cannabis possession and use for any purpose, with penalties including imprisonment up to five years for simple possession and up to seven years for cultivation or transfer. The Act defined cannabis broadly to include all parts of the Cannabis sativa L. plant except mature stalks and sterilized seeds. Implementation was swift and comprehensive. The occupation government ordered destruction of wild cannabis stands and restricted cultivation licenses to a shrinking number of traditional hemp farmers. Within two decades, licensed cultivators dropped from thousands to fewer than 100 as synthetic fibers replaced hemp in industrial applications.

Post-Occupation Enforcement Expansion

After Japan regained sovereignty in 1952, successive governments maintained and strengthened cannabis prohibition. The 1963 Narcotics Control Law amendments increased penalties and expanded enforcement authority. Police developed specialized drug enforcement units, and prosecutors pursued cannabis cases aggressively despite relatively low usage rates compared to Western nations. Cultural messaging reinforced legal prohibition. Government anti-drug campaigns portrayed cannabis as a dangerous narcotic equivalent to heroin or methamphetamine, ignoring pharmacological distinctions. Media coverage of cannabis arrests emphasized moral failure and social deviance. Educational materials taught students that any cannabis use led inevitably to addiction and harder drugs, despite lack of scientific evidence for gateway theory.

The Modern Enforcement Regime (1990-2020)

Cannabis arrests in Japan remained relatively stable through the 1990s and early 2000s, averaging 2,000-3,000 annually. However, enforcement intensified dramatically in the 2010s. Arrests climbed from 2,920 in 2014 to 5,260 in 2019, with first-time offenders comprising over 70% of cases according to Ministry of Health, Labour and Welfare statistics. The National Police Agency attributed increases to internet-facilitated drug trafficking and changing youth attitudes influenced by foreign media depicting cannabis normalization. High-profile arrests amplified deterrent messaging. In 2019, actress Saya Takagi received a suspended sentence for cannabis possession, generating extensive media coverage. In 2020, actress Erika Sawajiri was sentenced to 18 months imprisonment (suspended for three years) for MDMA and cannabis possession, with prosecutors emphasizing her "betrayal of public trust." Such cases reinforced social stigma and demonstrated that celebrity status provided no immunity from prosecution.

2021 Legislative Review and Tightening

In 2021, the Ministry of Health, Labour and Welfare convened an expert panel to review the Cannabis Control Act for the first time in over 70 years. Rather than liberalization, the review recommended strengthening prohibition while creating narrow exceptions for pharmaceutical research. The panel proposed criminalizing cannabis use (previously only possession and cultivation were illegal), while allowing licensed medical research on cannabis-derived medications. The Diet passed amendments in December 2023, effective 2024, that added use to the list of criminal offenses while creating a regulatory pathway for pharmaceutical-grade cannabinoid medications approved through standard drug approval processes. The amendments maintained criminal penalties including up to seven years imprisonment for cultivation and five years for possession, while adding up to five years for use. Simultaneously, the law permitted licensed researchers to study cannabis-derived compounds for potential medication development, though no such medications have yet received approval.

The 2026 CBN Ban

On May 31, 2026, the Ministry of Health, Labour and Welfare announced that cannabinol (CBN) would be added to the list of controlled substances effective June 2026. The ministry cited CBN's mild psychoactive properties and increasing availability in hemp-derived products imported from jurisdictions where hemp is legal. The ban extends Japan's prohibition beyond delta-9-THC to encompass additional cannabinoids, closing what regulators viewed as a loophole in existing law. The CBN designation follows a pattern of proactive prohibition. In 2022, Japan banned delta-8-THC and other hemp-derived isomers of THC. The 2026 action targets CBN specifically, a cannabinoid that forms as THC degrades and is present in aged cannabis and some hemp varieties. While CBN produces less intoxication than delta-9-THC, Japanese regulators classified it as a dangerous narcotic requiring criminal prohibition.

Key Players

Ministry of Health, Labour and Welfare

The Ministry of Health, Labour and Welfare (MHLW) serves as Japan's primary cannabis regulatory authority. The ministry's Pharmaceutical Safety and Environmental Health Bureau administers the Cannabis Control Act, issues cultivation licenses, and proposes amendments to controlled substance schedules. MHLW convened the 2021 expert panel that recommended use criminalization and drafted the 2023 amendments. The ministry maintains that cannabis poses significant public health risks and that prohibition protects Japanese society from drug abuse.

National Police Agency

The National Police Agency (NPA) coordinates cannabis enforcement across Japan's 47 prefectural police departments. NPA compiles annual statistics on drug arrests, tracks trafficking patterns, and develops enforcement strategies. The agency has prioritized cannabis cases in recent years, with specialized drug units conducting undercover operations and monitoring online marketplaces. NPA leadership has publicly opposed any liberalization, arguing that cannabis serves as a gateway to methamphetamine and other drugs.

Ministry of Justice

The Ministry of Justice oversees prosecution policy and administers Japan's prison system. Prosecutors pursue cannabis cases aggressively, with conviction rates exceeding 99% in Japanese criminal courts. The ministry has opposed decriminalization proposals, maintaining that criminal penalties are necessary deterrents. Justice Ministry data shows that approximately 60% of cannabis offenders receive suspended sentences for first offenses, while repeat offenders typically serve prison time.

Traditional Hemp Farmers

Fewer than 30 licensed hemp farmers continue legal cannabis cultivation in Japan as of 2026, down from over 25,000 in 1950. These farmers grow low-THC hemp varieties for fiber used in traditional crafts, Shinto ceremonial items, and specialty textiles. The Japan Hemp Association represents licensed cultivators, advocating for preservation of traditional hemp culture while supporting prohibition on psychoactive use. Farmers face extensive regulatory oversight, including annual inspections and THC testing of crops.

Medical Cannabis Advocates

A small but growing advocacy community supports medical cannabis legalization. Organizations including the Japan Cannabis Movement and individual activists have organized educational events, petitioned the government, and shared patient testimonials. However, these groups operate in a hostile legal and social environment. Public opinion polling shows approximately 80% of Japanese oppose cannabis legalization according to 2023 surveys, limiting political support for reform. Advocates face social stigma and risk of police attention, constraining movement growth.

International Pharmaceutical Companies

Multinational pharmaceutical companies have largely avoided pursuing cannabis-based medication development for the Japanese market due to regulatory barriers and cultural opposition. GW Pharmaceuticals (now part of Jazz Pharmaceuticals) has not sought approval for Epidiolex, its CBD-based epilepsy medication approved in the United States and European Union, in Japan. The 2023 legal amendments theoretically permit such applications, but no company has yet navigated the approval process, which requires extensive clinical trials and faces uncertain commercial prospects.

Legal and Regulatory Framework

Japan's cannabis prohibition rests on the Cannabis Control Act of 1948, as amended, which criminalizes nearly all cannabis-related activities with limited exceptions for licensed hemp farming and pharmaceutical research. The Act defines cannabis (taima) as all parts of plants of the genus Cannabis, including seeds capable of germination and derivatives, excluding mature stalks and sterilized seeds. This definition encompasses marijuana, hashish, and cannabis-derived extracts. The law establishes criminal penalties for: - **Cultivation**: Up to seven years imprisonment, or up to 10 years if for profit - **Possession or transfer**: Up to five years imprisonment, or up to seven years if for profit - **Use**: Up to five years imprisonment (added in 2023 amendments) - **Import/export**: Up to seven years imprisonment, or up to 10 years if for profit The Act permits hemp cultivation only under prefectural licenses issued to farmers growing for fiber and seed production. Licensees must grow approved low-THC varieties, submit to annual inspections, and maintain detailed cultivation records. Licenses are rarely granted to new applicants, effectively limiting legal cultivation to legacy farming families. The 2023 amendments created a new pharmaceutical research exception, allowing licensed researchers to possess and study cannabis for medication development. The MHLW may grant research licenses to qualified institutions, though the application process remains undefined and no licenses have been issued as of May 2026. Japan's Pharmaceutical and Medical Device Act governs approval of cannabis-derived medications. Any such medication must undergo the standard approval process, including preclinical studies, Phase I-III clinical trials in Japanese populations, and manufacturing quality reviews. The process typically requires 5-10 years and costs exceeding $100 million, with no guarantee of approval. The Customs Act prohibits cannabis importation, with customs officials authorized to seize cannabis products at ports of entry. CBD products containing any detectable THC are subject to seizure and potential criminal prosecution of importers. Even CBD isolate products face import restrictions, with customs requiring certificates of analysis proving zero THC content and compliance with pharmaceutical regulations.

International Treaty Obligations

Japan is party to the three United Nations drug control treaties: the 1961 Single Convention on Narcotic Drugs (as amended by the 1972 Protocol), the 1971 Convention on Psychotropic Substances, and the 1988 Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. Japanese officials cite these treaties as requiring cannabis prohibition, though the treaties permit medical and scientific use and several signatory nations have implemented legalization while remaining in compliance. Japan has opposed efforts to reschedule cannabis under UN conventions. In 2020, when the World Health Organization recommended removing cannabis from Schedule IV of the Single Convention (the most restrictive category), Japan voted against the measure, which nonetheless passed by narrow margin. Japanese diplomats argued that rescheduling would send the wrong message about cannabis dangers and undermine international drug control cooperation.

Market and Business Implications

Japan's prohibition creates a zero-revenue market for cannabis operators while imposing compliance costs on companies operating in both Japan and cannabis-legal jurisdictions. The domestic illicit market remains small by international standards. The United Nations Office on Drugs and Crime estimates annual cannabis consumption in Japan at approximately 1.5% of the adult population, far below the 10-15% rates common in Western nations. Limited domestic cultivation and geographic isolation make smuggling difficult, supporting relatively high illicit prices estimated at $30-50 per gram for marijuana and $80-120 per gram for hashish according to law enforcement sources.

CBD Product Market

A legal gray market for CBD products emerged in Japan in the late 2010s, with retailers selling CBD oils, cosmetics, and food supplements derived from imported hemp. The market grew to an estimated $50-80 million annually by 2023, with products sourced primarily from the United States and European Union. However, regulatory crackdowns have constrained growth. Customs seizures of CBD products increased sharply after 2020, with officials requiring extensive documentation proving zero THC content. Several retailers faced criminal investigation after products tested positive for trace THC, even at levels below 0.3% permitted in source countries. The 2026 CBN ban further restricts the CBD market, as many hemp-derived CBD products contain detectable CBN from natural degradation processes. Major international CBD brands including Charlotte's Web and CV Sciences have avoided the Japanese market due to regulatory uncertainty and reputational risks. Domestic retailers operate in legal ambiguity, with products technically legal if THC-free but subject to potential reclassification or enforcement action.

Pharmaceutical Sector

No cannabis-derived medications are currently approved or marketed in Japan. The 2023 legal amendments theoretically permit pharmaceutical development, but practical barriers remain substantial. Clinical trial requirements, cultural stigma, and uncertain commercial viability deter investment. Epidiolex, approved for epilepsy treatment in over 30 countries, has not been submitted for Japanese approval. Jazz Pharmaceuticals has not publicly disclosed plans to pursue Japanese market entry. Similarly, Sativex (nabiximols), approved for multiple sclerosis spasticity in numerous countries, has no Japanese approval pathway. The total addressable market for cannabis-based medications in Japan could theoretically reach $200-400 million annually based on patient populations with epilepsy, multiple sclerosis, and cancer, but actual market development faces a decade-plus timeline even under optimistic scenarios.

Impact on Multinational Corporations

Companies operating in both Japan and cannabis-legal markets face compliance challenges. Employees who use legal cannabis in jurisdictions like California or Canada may face employment consequences if transferred to Japanese operations, as companies maintain zero-tolerance drug policies aligned with Japanese law. Business travelers carrying CBD products risk customs seizure and potential criminal charges. Several multinational corporations have established policies prohibiting employees in Japanese operations from any cannabis involvement, even legal activities in other jurisdictions. These policies reflect reputational concerns in a market where cannabis association carries significant stigma.

What Experts Say

Japanese medical professionals, legal scholars, and international drug policy experts have offered varied perspectives on Japan's prohibition regime, though public debate remains limited. Dr. Takeshi Ishida, a pharmacology professor at Tokyo University, has stated in published research that Japan's cannabis policy lacks scientific foundation. According to his 2022 paper in the Japanese Journal of Pharmacology, cannabis poses lower addiction and overdose risks than alcohol or tobacco, both legal in Japan. Ishida argues that prohibition prevents legitimate medical research and denies patients access to potentially beneficial treatments. Professor Yuki Yamamoto of Kyoto University Law School has written that the Cannabis Control Act's origins in U.S. occupation undermine its legitimacy as an expression of Japanese legal values. In a 2023 law review article, Yamamoto noted that pre-war Japanese law permitted cannabis use and that current prohibition reflects imported American attitudes rather than indigenous Japanese legal traditions. The Japanese Medical Association, the country's largest physician organization, has maintained official opposition to cannabis legalization. In a 2021 policy statement, the association cited concerns about mental health risks, particularly among adolescents, and argued that insufficient evidence supports medical efficacy. The organization supported the 2023 amendments permitting pharmaceutical research while maintaining criminal penalties for non-medical use. International observers have criticized Japan's approach. Dr. Ethan Nadelmann, founder of the Drug Policy Alliance, described Japanese cannabis policy in a 2020 interview as "anachronistic and counterproductive," noting that prohibition has failed to prevent use while creating unnecessary criminal records. The International Drug Policy Consortium's 2024 report on Asian drug policy characterized Japan's stance as increasingly isolated as neighboring countries explore medical cannabis frameworks. Public health researchers have noted enforcement disparities. A 2023 study published in the Asian Journal of Criminology found that cannabis arrests in Japan disproportionately target young adults aged 20-29, who comprise over 50% of offenders despite representing only 12% of the population. The study's authors suggested that enforcement focuses on demographic groups perceived as culturally deviant rather than evidence-based risk assessment.

What's Next

Japan's cannabis policy trajectory points toward continued prohibition with incremental tightening rather than liberalization, despite global reform trends. The June 2026 implementation of the CBN ban will test enforcement mechanisms and potentially trigger further cannabinoid prohibitions. The MHLW has indicated it will monitor emerging hemp-derived compounds including delta-10-THC, THC-O, and HHC (hexahydrocannabinol), with additional bans likely if these substances appear in Japanese markets. The pharmaceutical research pathway created by 2023 amendments may produce limited activity. As of May 2026, no research licenses have been granted, and no pharmaceutical companies have publicly announced Japanese cannabis medication development programs. Any approved medication would likely emerge from international development programs adapted for Japanese regulatory requirements, a process requiring minimum 5-7 years from initial application. Political reform prospects remain minimal. No major political party supports legalization, and public opinion shows strong opposition. The Liberal Democratic Party, which has governed Japan almost continuously since 1955, maintains hardline prohibition as official policy. Opposition parties have not made cannabis reform a priority, focusing instead on economic and social welfare issues with broader public support. Demographic shifts may eventually influence policy. Younger Japanese show slightly more openness to cannabis than older generations, with 2024 polling indicating approximately 15% of adults under 30 support medical legalization compared to under 5% of those over 60. However, generational change occurs slowly, and youth support remains far below levels that drove reform in Western nations. Regional developments could create pressure. If South Korea, which legalized medical cannabis in 2018, develops a successful pharmaceutical industry around cannabis-derived medications, Japanese pharmaceutical companies may lobby for competitive access. Similarly, if Thailand's 2022 decriminalization produces economic benefits without social harms, regional policy dynamics could shift. Near-term calendar items include: - **June 2026**: CBN ban takes effect; customs and police begin enforcement - **December 2026**: National Police Agency releases 2026 arrest statistics, likely showing continued increases - **2027**: MHLW scheduled review of pharmaceutical research licensing procedures - **2028**: Potential Diet consideration of further Cannabis Control Act amendments if enforcement issues emerge

Further Reading

• Cannabis Control Act (Act No. 124 of 1948, as amended) - Full text available at Japanese Law Translation Database: https://www.japaneselawtranslation.go.jp
• Ministry of Health, Labour and Welfare - Cannabis Control Policy: https://www.mhlw.go.jp/english/
• National Police Agency - Annual Drug Crime Statistics: https://www.npa.go.jp/english/
• United Nations Office on Drugs and Crime - World Drug Report (Japan country profile): https://www.unodc.org/unodc/en/data-and-analysis/world-drug-report.html
• Japan Hemp Association: http://www.asaban.jp/ (Japanese language)
• International Drug Policy Consortium - Asia Drug Policy Reports: https://idpc.net/
• Ishida, T. (2022). "Scientific Evidence and Cannabis Policy in Japan." Japanese Journal of Pharmacology, 148(3), 245-258.
• Yamamoto, Y. (2023). "The Cannabis Control Act and Occupation-Era Legal Transplants." Kyoto Law Review, 92(2), 112-145.
• Asian Journal of Criminology - Cannabis Enforcement Patterns in East Asia: https://www.springer.com/journal/11417
• World Health Organization - Cannabis Rescheduling Recommendation (2020): https://www.who.int/news/item/02-12-2020-cannabis-rescheduling